Leveraging Class Action Litigation to Recover Losses in Reckitt Benckiser: Act Before August 4, 2025 Deadline

Investors in Reckitt Benckiser Group PLC (OTC: RBGLY) face a critical opportunity to recover losses tied to a securities fraud lawsuit alleging material misstatements regarding risks associated with its Enfamil infant formula. With a lead plaintiff deadline looming on August 4, 2025, the case presents a strategic path for shareholders to seek compensation without upfront costs—a rare chance in an era of corporate accountability challenges.

The Case: Material Misstatements and Investor Harm

The lawsuit, filed by multiple law firms including Rosen Law Firm, Levi & Korsinsky, LLP, and others, accuses Reckitt Benckiser of misleading investors about risks tied to its Enfamil cow's milk-based formula. Specifically, the company allegedly failed to disclose that preterm infants consuming Enfamil faced a heightened risk of necrotizing enterocolitis (NEC), a life-threatening gastrointestinal condition. This omission, plaintiffs argue, artificially inflated stock prices by obscuring legal and financial risks.

Key allegations include:
- Concealed Health Risks: Reckitt Benckiser allegedly knew of studies linking Enfamil's ingredients to NEC but did not disclose these findings.
- Downplayed Legal Exposure: The company did not adequately warn investors of the surge in lawsuits, including a $60 million verdict in March 得罪 2024 and a $495 million ruling in July 2024, which triggered significant stock declines.
- Misleading Statements: Executives allegedly assured investors of Enfamil's safety and market resilience during earnings calls, despite mounting evidence to the contrary.

Why Act Before August 4, 2025?

The lead plaintiff deadline is a pivotal moment for shareholders who purchased RBGLY shares between January 13, 2021, and July 28, 2024. Becoming the lead plaintiff grants influence over case strategy and settlement terms. Even without this role, participation is free under a contingency fee structure, meaning legal costs are only paid if the case succeeds.

This data will show the stock's sharp drops—14% post-March 2024 verdict and nearly 9% after July 2024's Similac ruling—highlighting the material impact of litigation on investor value.

Strategic Advantages of Participation

1. Recovery Potential: Successful class actions often settle for millions. For example, Enfamil-related verdicts have already reached over $60 million, with bellwether trials scheduled through February 2026. Early participation increases the chance of fair compensation.
2. Law Firm Track Records:
3. Rosen Law Firm, ranked No. 1 in securities class action recoveries (2017), has secured over $5 billion for investors.
4. Levi & Korsinsky, LLP, with decades of experience, has recovered hundreds of millions in shareholder suits.
5. Gross Law Firm and others specialize in holding corporations accountable for fraud.
6. Avoiding Legal Exclusion: Missing the deadline could bar eligibility for settlements, especially if the court certifies a class.

Risks of Inaction

• Missed Recovery Opportunities: Delayed action risks exclusion from settlements or favorable terms.
• Erosion of Value: Reckitt Benckiser's stock remains vulnerable to adverse rulings, with further declines likely if the company faces massive liabilities.
• Legal Costs: Non-participating shareholders may still bear costs if the company shifts expenses to shareholders.

A Roadmap for Investors

1. Register by August 4, 2025: Use submission forms provided by law firms (e.g., Rosen Law's portal at
   rosenlegal.com) to secure eligibility.
2. Engage Counsel: Even without lead plaintiff status, retaining experienced attorneys maximizes recovery odds.
3. Monitor Developments: Track bellwether trials and settlements via the MDL-3026 case, which could accelerate resolutions.

Conclusion: A Calculated Move for Recovery

The Reckitt Benckiser case is a stark reminder of the risks of corporate opacity—and the power of collective action. For investors holding RBGLY during the class period, acting before August 4, 2025, is not just prudent but essential. With contingency fees eliminating upfront costs, there's little downside to participating.

Final Advice: Do not let this deadline pass. Secure your position in the case now to protect your investment and hold Reckitt Benckiser accountable for its alleged misconduct.

Disclaimer: This analysis is for informational purposes. Consult legal counsel to assess eligibility and strategy.